Sign in to fuzzto save your conversations, follow your research and come back anytime.
Gufic BioSciences
GUFICBIO
NSE
BSE
NSEBSESectorHealthcare
439.35
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Gufic Bio delivers strong revenue growth and margin expansion through Q1 FY27, with profits nearly doubling.
Revenue grew from ₹226.9 Cr to ₹260.8 Cr from Q1 FY26 to Q1 FY27, signaling steady demand and market share gains.
Tax provisions increased from ₹4.2 Cr to ₹8.2 Cr from Q1 FY26 to Q1 FY27, tracking higher profitability.
EBITDA expanded from ₹33.2 Cr to ₹47.2 Cr from Q1 FY26 to Q1 FY27, reflecting robust operational cash generation.
EBITDA margin rose from 14.63% to 18.09% from Q1 FY26 to Q1 FY27, confirming sustained pricing power and cost control.
Profit After Tax climbed from ₹12.1 Cr to ₹22.0 Cr from Q1 FY26 to Q1 FY27, demonstrating accelerating net earnings.